et al. Fluoropyrimidine (FP) 1 bevacizumab (BEV) 1 atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from cohort 2 of MODUL–a multicentre, randomized trial of biomarkerdriven maintenance treatment following first-line induction therapy. Ann.